Yousif Capital Management LLC Purchases 14,828 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

Yousif Capital Management LLC increased its position in OraSure Technologies, Inc. (NASDAQ:OSUR) by 40.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 51,786 shares of the medical instruments supplier’s stock after acquiring an additional 14,828 shares during the quarter. Yousif Capital Management LLC’s holdings in OraSure Technologies were worth $425,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in OraSure Technologies by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 5,396,285 shares of the medical instruments supplier’s stock worth $32,000,000 after purchasing an additional 64,367 shares in the last quarter. Cannell Capital LLC boosted its stake in OraSure Technologies by 36.5% in the 3rd quarter. Cannell Capital LLC now owns 2,820,591 shares of the medical instruments supplier’s stock worth $16,726,000 after purchasing an additional 753,901 shares in the last quarter. Pacer Advisors Inc. lifted its stake in OraSure Technologies by 122.5% during the 4th quarter. Pacer Advisors Inc. now owns 2,403,333 shares of the medical instruments supplier’s stock valued at $19,707,000 after acquiring an additional 1,323,197 shares during the period. Invesco Ltd. lifted its stake in OraSure Technologies by 4.9% during the 3rd quarter. Invesco Ltd. now owns 1,282,378 shares of the medical instruments supplier’s stock valued at $7,605,000 after acquiring an additional 59,801 shares during the period. Finally, AQR Capital Management LLC lifted its stake in OraSure Technologies by 118.0% during the 3rd quarter. AQR Capital Management LLC now owns 935,510 shares of the medical instruments supplier’s stock valued at $5,548,000 after acquiring an additional 506,312 shares during the period. Institutional investors own 93.50% of the company’s stock.

OraSure Technologies Trading Up 0.2 %

OraSure Technologies stock opened at $5.50 on Tuesday. The firm has a 50 day moving average of $6.15 and a 200 day moving average of $6.81. The firm has a market capitalization of $420.81 million, a price-to-earnings ratio of 7.64 and a beta of 0.23. OraSure Technologies, Inc. has a 12-month low of $4.38 and a 12-month high of $8.45.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.09. The company had revenue of $75.88 million during the quarter, compared to analyst estimates of $74.13 million. OraSure Technologies had a net margin of 13.23% and a return on equity of 14.50%. The firm’s quarterly revenue was down 38.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.21 EPS. On average, analysts predict that OraSure Technologies, Inc. will post -0.11 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on OSUR shares. StockNews.com upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Wednesday, May 1st. Evercore ISI lowered their target price on shares of OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating on the stock in a research note on Thursday, April 4th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $6.38.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.